Why Genetic and Molecular Testing Comes First in Acute Myelogenous Leukemia Treatment

The call usually comes fast. A routine blood test, then a phone message asking you to come in today, then a hematologist explaining that the marrow sample from this morning shows acute myelogenous leukemia. Most people in that chair expect the next sentence to be about chemotherapy starting tonight. Instead, the doctor often says something that feels backwards: we need to wait for the genetics.

That pause is not hesitation. In AML, genetic testing and treatment are tied together so tightly that starting without the results can mean choosing the wrong road at the first junction. Two people with the same diagnosis, the same blood counts and the same symptoms can carry completely different leukemias at the molecular level, and those differences now change what is prescribed, for how long, and whether a transplant enters the conversation.

This article explains what the laboratory is actually looking for, why the first few days are structured the way they are, and what the results can and cannot tell you.

What does genetic and molecular testing mean in AML?

Acute myelogenous leukemia, also called acute myeloid leukemia or AML, is a cancer of the blood-forming cells in the bone marrow, the spongy tissue inside bones where blood is made. In AML, immature cells called myeloblasts multiply quickly and crowd out normal red cells, white cells and platelets. That is the shared picture. Underneath it, the leukemia cells in each person carry their own set of acquired changes to their DNA, and those changes behave like a fingerprint.

Genetic testing in this setting has two layers. The first is cytogenetics, the study of chromosomes, the 46 packaged bundles of DNA inside each cell. Pathologists look for pieces that have broken off and swapped places, called translocations, or for missing or extra copies. The second layer is molecular testing, which reads the sequence of individual genes to find small spelling errors, called mutations, that a chromosome view would miss.

Neither test looks at the DNA you inherited from your parents. They examine the leukemia cells themselves, which is why a positive result does not automatically mean a family risk. Inherited risk is a separate question, covered later.

Why does this matter so much in AML in particular? Because the World Health Organization and major hematology guidelines now classify many AML subtypes by their genetic defect rather than by how the cells look under a microscope. According to the National Cancer Institute, the subtype and the specific chromosome and gene changes are central to planning treatment. A microscope can confirm leukemia; only the genetic report can say which leukemia, and modern treatment is written for the specific one.

Why AML genetic testing comes before treatment decisions

Picture two patients admitted on the same evening. Both have a high white cell count, both are exhausted, both have bruises they cannot explain. By the end of the week the laboratory reports that one carries a change in a gene called NPM1 without a second change in FLT3, and the other has a loss of chromosome 17 that removes the TP53 gene, often alongside several other chromosome breaks. The Mayo Clinic notes that doctors use exactly these kinds of results to determine prognosis and to shape the treatment plan.

For the first patient, standard intensive chemotherapy may be the main plan, with a transplant held in reserve. For the second, chemotherapy alone tends to be less effective, and the team will usually begin discussing a donor search and a stem cell transplant from the outset, alongside less intensive drug combinations if the person is not fit for high-dose treatment. Same diagnosis, two very different first weeks.

Then there are the additions. Several approved medicines work only when a specific mutation is present: FLT3 inhibitors for FLT3 mutations, IDH1 or IDH2 inhibitors for those genes. Giving such a drug without the matching mutation offers side effects without benefit, so the result has to arrive before the prescription is written.

There is one more reason, and it is about timing. Some molecular tests can be run quickly, but full chromosome analysis requires leukemia cells to be grown in culture for a few days. Teams therefore order a short list of urgent tests, start supportive care such as transfusions and antibiotics, and plan the main treatment around when the key results will return. The wait is scheduled, not accidental.

What actually happens: the bone marrow sample and the lab

Almost everything starts with a bone marrow aspiration and biopsy. A clinician numbs the skin over the back of the pelvis, passes a hollow needle into the bone, and draws out liquid marrow, followed by a small core of solid marrow. MedlinePlus describes the procedure as taking a few minutes, with a sensation of pressure and a brief deep ache as the liquid is drawn. Soreness for a day or two afterwards is common.

That one sample is divided several ways:

• Morphology: a pathologist counts the proportion of immature cells and notes their appearance.
• Flow cytometry: cells are tagged with fluorescent markers to identify which proteins sit on their surface, confirming they are myeloid rather than lymphoid.
• Karyotype: leukemia cells are grown for several days, then photographed mid-division so each chromosome can be examined.
• FISH: fluorescence in situ hybridization uses glowing probes that stick to specific chromosome regions, giving a quicker answer about a handful of known rearrangements.
• Molecular sequencing: a panel of genes, often dozens at once, is read letter by letter to find mutations.

Blood is also sent, and if the circulating blast count is high, some tests can be run on blood alone. The Cleveland Clinic lists bone marrow examination, cytogenetic studies and molecular testing together as the standard diagnostic set for AML.

Results arrive in waves. Morphology and flow cytometry can be reported within a day or so. Rapid molecular results for a few genes tend to follow within days. The complete karyotype and the full sequencing panel usually take longer. Your team will tell you which results they are waiting for and which decision each one unlocks.

Which genetic mutations in AML matter most, and what each tells your team

Dozens of genes can be altered in AML, but a shorter list drives most decisions. The table below groups the ones patients hear about most often. It is a guide to the conversation, not a prognosis calculator; your report will be interpreted alongside your age, overall health and how the leukemia responds.

Change found	What it is	Why the team cares
t(15;17), PML-RARA	Chromosome swap defining acute promyelocytic leukemia	Needs a different, urgent treatment approach
t(8;21) or inv(16)	Core-binding factor rearrangements	Generally associated with a more favorable outlook
NPM1 mutation	Common gene mutation in AML with normal chromosomes	Favorable when FLT3-ITD is absent; useful for tracking residual disease
FLT3-ITD	Internal duplication in a growth-signal gene	Drives rapid growth; matched inhibitors exist
IDH1 or IDH2 mutation	Metabolic enzyme genes	Matched inhibitors exist; relevant to later treatment choices
TP53 mutation or complex karyotype	Loss of a key tumor-suppressor gene; three or more chromosome abnormalities	Adverse group; chemotherapy alone less effective, transplant usually discussed
KMT2A rearrangements	Chromosome 11 swaps	Risk varies by partner gene; some have matched investigational drugs

Two features of this list are worth underlining. First, mutations travel in combinations, and the combination matters more than any single entry; NPM1 is the clearest example, read differently depending on whether FLT3-ITD sits beside it. Second, several of these changes do double duty: they inform the initial plan and also become the marker the laboratory follows months later to see whether leukemia is lingering below the level a microscope can detect. The National Cancer Institute describes cytogenetic and molecular findings as among the main factors determining both treatment options and outlook.

How AML prognosis by mutation is grouped into risk categories

Hematologists do not read a genetic report as a loose list. They sort the findings into risk groups, most commonly using the European LeukemiaNet framework, which places each genetic profile into a favorable, intermediate or adverse category. The word prognosis here means the likely course of the disease and how it is expected to respond to treatment, not a verdict on any individual.

The favorable group includes the core-binding factor rearrangements, NPM1 mutations without FLT3-ITD, and certain CEBPA mutations. Intermediate covers a mixed middle, including many people whose chromosomes look normal but who carry mutations that neither clearly help nor clearly hurt. The adverse group contains TP53 mutations, complex karyotypes, certain chromosome 5 and 7 losses, and some specific rearrangements.

The risk group answers one central question: is standard chemotherapy, on its own, likely to be enough? For favorable-risk disease, the usual plan is intensive chemotherapy followed by further chemotherapy cycles, with transplant held back unless the leukemia returns. For adverse-risk disease, teams generally plan for a stem cell transplant in first remission, because the chance of relapse after chemotherapy alone is judged too high. Intermediate risk is where the discussion is longest and most individual, and where measurable residual disease results after the first cycle often tip the decision.

Three honest caveats. Risk groups are updated as evidence accumulates, so a category assigned a few years ago might sit differently today. The groups were built mostly from data on people fit enough for intensive treatment, so they translate imperfectly to older or frailer patients. And a category describes populations, not people; your response to the first cycle is itself a powerful piece of information that the genetics cannot replace.

One result that changes everything within hours: acute promyelocytic leukemia

If you want a single example of why testing comes first, this is it. Acute promyelocytic leukemia, or APL, is a subtype of AML defined by a swap between chromosomes 15 and 17 that fuses two genes, PML and RARA. The fused gene jams the maturation of white cells at one stage, and the stuck cells release substances that disrupt clotting. The National Cancer Institute lists APL as a distinct AML subtype that is treated differently from the others.

Two things follow. First, bleeding and clotting problems are the most dangerous early feature of APL, more than infection or anemia, so supportive care focuses heavily on platelets and clotting factors from the first hours. Second, the treatment is not the standard chemotherapy backbone used for other AML. APL responds to differentiation therapy: medicines in the retinoid class, related to vitamin A, and arsenic-based agents that unjam the stuck cells and let them mature and die naturally. Giving the usual intensive chemotherapy to someone with APL, or delaying the differentiation agent, can worsen the clotting crisis.

This is why many centers run a rapid PML-RARA test, or begin a retinoid on suspicion while the result is pending, when the microscope picture and the clotting tests raise the possibility. The genetic test confirms or rules it out quickly, and the entire plan pivots on the answer.

APL also carries a specific treatment-related risk called differentiation syndrome, in which maturing cells cause fluid build-up, fever and breathing difficulty. Teams watch for it closely in the first days and weeks. The decision to start, continue or adjust any of these medicines sits entirely with the treating hematologist.

How AML targeted therapy works, and what it adds

Targeted therapy means a medicine designed to interfere with a specific molecular feature of the cancer cell rather than attacking all fast-dividing cells. In AML, several such medicines exist, and each is matched to a result on the genetic report. The Mayo Clinic describes targeted drug treatments as focusing on specific abnormalities within cancer cells and notes that doctors test leukemia cells to see whether such treatments may help.

The main classes, described by mechanism only:

• FLT3 inhibitors block a receptor that, when mutated, sends constant grow-and-divide signals. They are generally combined with chemotherapy at the start and sometimes continued afterwards.
• IDH1 and IDH2 inhibitors switch off a faulty enzyme whose abnormal byproduct prevents cells from maturing. Removing the byproduct lets the blocked cells differentiate.
• BCL-2 inhibitors (venetoclax is the generic name) disable a protein that leukemia cells use to resist programmed cell death. This class is not tied to one mutation and is usually combined with a hypomethylating agent, a gentler chemotherapy that reactivates silenced genes.
• Menin inhibitors, a newer class, interrupt a protein partnership that certain KMT2A-rearranged and NPM1-mutated leukemias depend on.

What targeted therapy adds is precision, not a replacement for everything else. Most of these agents are used alongside chemotherapy or as part of a combination, and they bring their own side effects, including interactions with other medicines, effects on heart rhythm for some, and the differentiation syndrome mentioned earlier for others. Their value depends entirely on the match between drug and mutation, which is the practical reason testing precedes prescribing.

Whether any of these belongs in your plan is a judgment your hematologist makes from your full report, your other health conditions and current guideline evidence.

Who is usually treated intensively, and who is usually offered a different path

The genetic report answers which treatment; a second assessment answers which treatment you can safely receive. The two are weighed together, and this is where the plan becomes personal.

Intensive induction chemotherapy, the traditional combination of an anthracycline and cytarabine often called 7+3 for the number of days each is given, wipes out the marrow almost entirely and requires several weeks in hospital while blood counts recover. The NHS notes that this phase is usually given in hospital over a period of weeks because of the risk of infection and bleeding while counts are low. It is generally offered to people whose heart, kidney, liver and lung function can tolerate it, regardless of chronological age.

A less intensive approach, usually a hypomethylating agent with or without a BCL-2 inhibitor, is commonly offered to people who are older or who have significant other illnesses. This path is often delivered largely as an outpatient and has reshaped what treatment looks like for the many people diagnosed later in life. Genetic results still matter here: IDH mutations, for example, may open an additional option.

Who is usually asked to wait? In practice, almost everyone waits a few days for key results, but two groups wait longer by design. People with a borderline or unclear subtype may have treatment timed to the full panel. And people being considered for a clinical trial are often held until eligibility testing is complete, because trials of targeted agents require the matching mutation to be confirmed first.

Fitness assessment is itself structured, often using performance scores and organ-function tests, and the final recommendation always comes from the treating team after the whole picture is assembled.

Is AML hereditary? Germline testing and what it means for family

Most AML is not inherited. The mutations found in leukemia cells are acquired during a person’s lifetime, through aging, chance errors in cell division, prior chemotherapy or radiation, or exposure to certain chemicals. MedlinePlus lists age, prior cancer treatment and chemical exposures among the recognized risk factors, and notes that most people with AML have no identifiable cause.

A small proportion of cases, however, arise in people who inherited a predisposing change in every cell of the body. Genes recognized in this group include RUNX1, CEBPA, DDX41, GATA2 and ANKRD26, among others. A germline mutation means one present from birth in all cells; a somatic mutation means one acquired only in the leukemia cells. Standard leukemia panels test the cancer cells and cannot reliably tell the two apart, so when a result raises suspicion, the team may order a separate test on skin cells or cultured cells, which do not contain leukemia.

Why does this distinction matter for treatment? Two reasons stand out. If a stem cell transplant is planned and a sibling is being considered as a donor, the team needs to know the sibling does not carry the same predisposing gene. And some inherited syndromes affect how a person tolerates particular treatments, or carry risks for other organs that need monitoring.

Clues that prompt germline testing include a diagnosis at a young age, a family history of blood cancers or unexplained low counts, certain mutations appearing at a proportion suggesting they are in every cell, or specific genes on the panel. Genetic counseling is usually offered before and after, because results affect relatives, and testing of family members is always their own choice.

What the first days and weeks usually look like

The opening phase of AML care has a rhythm, and knowing it helps the waiting feel less like a void. Timelines below are typical ranges drawn from patient guidance, not promises, and your own schedule will be set by your team.

Days one to three. Admission, blood tests, the marrow sample, and a chest X-ray or heart scan to check fitness for chemotherapy. Supportive care begins immediately: transfusions of red cells or platelets if counts are low, antibiotics if there is any fever, and fluids and medicines to protect the kidneys from the breakdown products of dying leukemia cells. A central line, a soft tube placed in a large vein, is often inserted for the months ahead. Rapid molecular tests are sent, and if APL is suspected, that question is prioritized above everything else.

Days three to seven. Morphology and flow cytometry are back. Rapid results for genes such as FLT3 and the PML-RARA fusion often return in this window, and for many people the main treatment begins during this week with the knowledge of which, if any, targeted agent to add. The full karyotype and extended sequencing panel may still be pending.

Weeks two to four. If intensive induction has started, blood counts fall to their lowest point and infection risk peaks; this is the stretch spent largely in hospital. The complete genetic report arrives and the risk category is finalized. Discussions about a transplant, where relevant, typically begin now, including tissue typing of siblings.

Around week four. A repeat marrow test checks whether the leukemia has responded and, increasingly, how much measurable residual disease remains. The NHS describes induction as lasting several weeks and notes that further cycles, called consolidation, follow once remission is confirmed.

How AML genetic testing guides treatment after remission

Remission means the marrow no longer shows excess leukemia cells under the microscope and blood counts have recovered. It is a milestone, not a finish line, because a microscope can only see down to roughly one leukemia cell in a few hundred. The same genetic tools used at diagnosis are now turned to a more sensitive question: how much leukemia is left below that threshold?

This is called measurable residual disease, or MRD. Two main methods are used. Flow cytometry can detect abnormal cells at much lower levels than morphology. Molecular methods go further still, using the specific mutation or fusion found at diagnosis, most reliably NPM1, PML-RARA and the core-binding factor fusions, as a tag that can be tracked in blood or marrow at very low levels. Newer sequencing-based methods are extending this to other genes.

MRD results feed directly back into the plan. A person with intermediate-risk genetics who becomes MRD-negative after induction may be steered toward chemotherapy consolidation rather than transplant; one who remains MRD-positive may be steered the other way. After transplant or during maintenance treatment, a rising MRD signal can prompt earlier intervention than waiting for counts to fall.

Monitoring continues for a period after treatment ends, with blood and sometimes marrow tests at intervals your team sets. Relapsed leukemia is often retested from scratch, because the mutation profile can shift: a FLT3 mutation present at diagnosis may disappear, or a new IDH or TP53 change may appear, which changes which targeted agent, if any, is relevant. In this sense genetic testing in AML is not a single event but a thread running through the whole course of care.

What is the most successful treatment for AML? An honest answer

People type this question into search engines constantly, and the honest answer is that it has no single reply, because AML is not a single disease. The treatment with the best evidence for one genetic subtype can be a poor choice for another. That is the entire reason this article exists.

Some patterns are well established in guideline-level evidence. For acute promyelocytic leukemia, differentiation therapy with retinoid and arsenic-based agents has transformed the outlook and is the standard approach. For fit adults with other AML subtypes, intensive chemotherapy remains the backbone, with a matched targeted agent added when the relevant mutation is present. For adverse-risk disease, a stem cell transplant from a donor offers the best chance of long-term control for those able to undergo it. For people not fit for intensive treatment, a hypomethylating agent combined with a BCL-2 inhibitor has become a widely used standard. The National Cancer Institute’s patient summary describes all of these as standard treatment approaches, selected by subtype, risk group and overall health.

What this means in practice is that the question to ask is not what is the best AML treatment but what is the best-supported treatment for my AML. Outcome statistics quoted online usually describe broad populations and often predate several of the medicines now in routine use, so they rarely describe your situation accurately.

Clinical trials sit alongside the standards rather than beneath them. Many current trials test the addition of a targeted agent to an existing regimen in people with a specific mutation, which is another reason complete genetic testing happens first: it determines which trials, if any, you are eligible to join. Your treating team can tell you whether one is appropriate.

What people often get wrong about AML genetic testing

Waiting for results means the doctors are not sure. The wait is planned around the test that unlocks the next decision. Supportive care, and sometimes a first medicine, begins immediately; the main regimen is timed to the information that shapes it.

A mutation means my children are at risk. Almost all mutations found on an AML panel are somatic, present only in the leukemia cells, and cannot be passed on. Inherited predisposition is uncommon and is investigated with a separate germline test when specific clues appear.

Favorable risk means mild leukemia. All AML is acute and life-threatening without treatment. Favorable describes how the disease is expected to respond to standard therapy, not how urgent it is.

Adverse risk means nothing will work. Adverse means chemotherapy alone is less likely to be enough, which is precisely why transplant and newer combinations enter the plan early. The category changes the strategy; it does not end it.

A targeted drug is gentler than chemotherapy. Targeted agents are more selective, but they carry real side effects of their own, including heart rhythm effects, liver effects and differentiation syndrome depending on the class, and most are given together with chemotherapy rather than instead of it.

Finding a blood mutation on a general health test means I have leukemia. Clonal hematopoiesis of indeterminate potential, or CHIP, is the presence of a leukemia-associated mutation in a small proportion of blood cells in someone with normal counts and no disease. It becomes more common with age and raises long-term risk modestly, but the large majority of people with CHIP never develop AML. It is monitored, not treated.

The genetic report at diagnosis is final. Leukemia evolves. Relapsed disease is usually retested because the profile, and therefore the options, may have changed.

Questions to ask your care team

Appointments in the first week are crowded with information, and it helps to arrive with questions written down. The list below is organized around the decisions your genetic results will shape. Nothing here replaces your team’s judgment; it is meant to help you follow their reasoning.

• Which genetic and molecular tests have been sent, and which result are you waiting for before starting the main treatment?
• Has acute promyelocytic leukemia been ruled out, and if not, what is being done in the meantime?
• What mutations or chromosome changes were found, and which risk group do they place me in?
• Does any mutation on my report match an approved targeted therapy, and would you recommend adding it? Why or why not?
• Based on my genetics and my overall health, are you recommending intensive chemotherapy or a less intensive approach?
• Is a stem cell transplant likely to be part of my plan, and when would that decision be made?
• Should my siblings be tissue-typed now, and is there any reason to test them for an inherited gene before considering them as donors?
• Is there anything in my report or family history that suggests germline testing or a referral to a genetic counselor?
• How and when will you measure residual disease after the first cycle, and how will that result change the plan?
• Am I eligible for any clinical trial based on my mutation profile?
• If the leukemia returns, will the genetic tests be repeated?
• Who do I call, at any hour, if I develop a fever or bleeding at home?

Ask for a copy of the pathology and genetic reports. They are dense, but having them means the next clinician you see can read exactly what the first one read, and you can revisit them as your understanding grows.

When to call your doctor

Treatment for AML lowers normal blood counts before it restores them, and the medicines described above have their own warning signs. Your team will give you a 24-hour contact number; use it without hesitation, and treat the following as reasons to call immediately or go to the emergency department.

• A temperature at or above the threshold your team specified, or chills and shaking even without a measured fever. Low white cell counts mean infection can escalate within hours, and MedlinePlus advises prompt medical attention for fever during leukemia treatment.
• Bleeding that does not stop with gentle pressure, blood in urine or stool, vomiting blood, a sudden crop of pinpoint red spots on the skin, or a severe headache with confusion or weakness, which can signal bleeding inside the head when platelets are low.
• New shortness of breath, chest pain, a racing or irregular heartbeat, or fainting.
• Rapid weight gain, swelling, fever and breathing difficulty while taking a retinoid, arsenic-based agent, or an IDH or menin inhibitor, which may indicate differentiation syndrome.
• Severe mouth sores or diarrhea that prevent you from drinking, or signs of dehydration such as very dark urine or dizziness on standing.
• Redness, pain, swelling or discharge around a central line.
• A rash, hives, lip swelling or wheeze after a new medicine or transfusion.

Between emergencies, keep a note of anything new and raise it at the next visit: bruising patterns, persistent tiredness beyond what you were told to expect, mood changes, or questions about your genetic report that occurred to you at home. Nothing is too small to mention, and the people who know your mutation profile are the right ones to interpret what any new symptom might mean. Every decision about starting, continuing or changing treatment rests with your treating team.

Frequently asked questions

Is there genetic testing for AML?

Yes, and it is a standard part of diagnosis rather than an optional extra. Leukemia cells from a bone marrow sample are examined for chromosome changes by karyotype and FISH, and for gene mutations by molecular sequencing panels that often cover dozens of genes at once. Results arrive in stages over roughly the first one to three weeks and are used to classify the subtype, assign a risk group and choose treatment.

What is the most successful treatment for AML?

There is no single best treatment, because AML is a group of genetically different diseases. Differentiation therapy is the standard for acute promyelocytic leukemia, intensive chemotherapy with or without a matched targeted agent is the backbone for fit adults with other subtypes, a donor stem cell transplant is usually planned for adverse-risk disease, and less intensive drug combinations are standard for people not fit for high-dose treatment.

What is the prognosis for patients with AML with mutations?

It depends on which mutations are present and in what combination. NPM1 without FLT3-ITD and the core-binding factor rearrangements fall into a favorable group; TP53 mutations and complex karyotypes fall into an adverse group; many others sit in between. These categories describe how populations respond to standard treatment, and your own response after the first cycle adds information no genetic test can provide.

At what age does AML typically start?

AML can occur at any age, including in children, but it is primarily a disease of older adults. The Mayo Clinic notes that risk rises with age and that AML is most common in adults aged 65 and older. Age itself does not determine treatment; fitness and genetic risk do, and many older adults are now treated with less intensive combinations guided by the same genetic results.

What are the most common genetic mutations in AML?

Mutations in NPM1, FLT3, DNMT3A, IDH1, IDH2, TET2, RUNX1 and TP53 are among the most frequently reported, alongside chromosome rearrangements such as t(8;21), inv(16) and t(15;17). Frequency and significance differ; DNMT3A is common but carries little treatment implication on its own, while FLT3-ITD and IDH mutations directly open the possibility of matched targeted therapy.

How does AML targeted therapy differ from chemotherapy?

Chemotherapy damages all rapidly dividing cells, including healthy marrow. Targeted therapy blocks a specific molecular feature of the leukemia cell, such as a mutated FLT3 receptor or IDH enzyme, or a survival protein like BCL-2. Most targeted agents are given alongside chemotherapy rather than instead of it, and they have their own side effects, so they are selected only when the genetic report shows the matching target.

Is AML hereditary?

Usually not. The mutations found in AML cells are acquired during life and cannot be passed on. A small minority of cases arise from an inherited predisposition involving genes such as RUNX1, CEBPA, DDX41 or GATA2. When a young age at diagnosis, a family history of blood problems or a suspicious result on the leukemia panel appears, a separate germline test on non-leukemia cells and genetic counseling are offered.

Does AML prognosis by mutation change over time?

Yes, in two ways. Risk classifications are revised as new evidence and new medicines arrive, so the meaning of a given mutation can shift between guideline editions. And the leukemia itself evolves: a mutation present at diagnosis may disappear at relapse while a new one appears. This is why relapsed AML is retested rather than treated from the original report.

Why can't AML treatment start on the day of diagnosis?

Supportive care, including transfusions, antibiotics and kidney protection, does start immediately. The main anti-leukemia regimen is often timed to the arrival of rapid genetic results because those results determine whether a targeted agent should be added, whether the disease is acute promyelocytic leukemia requiring a different approach, and which clinical trials might be open. Full chromosome analysis requires cells to be cultured for several days.

What does measurable residual disease mean in AML?

Measurable residual disease, or MRD, is leukemia present at levels too low for a microscope to see but detectable by flow cytometry or by molecular tests that track the specific mutation found at diagnosis. MRD results after the first treatment cycle help decide whether chemotherapy consolidation is enough or whether a stem cell transplant should be planned, and rising MRD during follow-up can prompt earlier action.

References

• NHS: Acute myeloid leukaemia, treatment
• MedlinePlus: Acute myeloid leukemia, adult

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.